Author:
Grimminger F.,Walmrath D.,Seeger W.
Publisher
Springer Berlin Heidelberg
Reference84 articles.
1. Abenhaim L, Moride Y, Brenot F et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609–616.
2. Adnot S, Andrivet P, Chabrier PE et al. (1989) Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. J Clin Invest 83: 986–993.
3. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B (1992) Short and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102: 1407–1412.
4. Archer SL, Souil E, Dihn-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi E (1998) Molecular identification of the role of voltage-tagged K+ channels, Kv 1.5 and 2.1 in hypoxic pulmonary vasoconstriction and control of resting membrane potentials in rat arterial myocytes. J Clin Invest 10: 1–12.
5. Archer SL, Kjaballah K, Humbert M, Weir EK, Fartoukh M, Simmonneau G, Dinh-Yuan AT (1998) Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine. Am J Respir Crit Med 157: 594.